Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX-826 for androgenetic alopecia in Chinese adult men (Phase II)
CTR20201655Phase 2Completed
- Sponsor
- Suzhou Kaixi Pharmaceutical
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pyrilutamide in androgenetic alopecia (AGA), sponsored by Suzhou Kaixi Pharmaceutical. Started Aug 2020; status: completed.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on CTR20201655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201655.